The current therapeutic strategy for NSCLC is molecular targeted therapy such as the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for NSCLC with EGFR gene mutation [18,19,20]. Here, EGFR is linked to non-small cell lung carcinoma.